GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET REPORT, HISTORY AND FORECAST 2018-2033, BREAKDOWN DATA BY COMPANIES, KEY REGIONS, TYPES AND APPLICATION
Peptide and Oligonucleotide CDMO report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Peptide and Oligonucleotide CDMO market is projected to reach US$ 3117.9 million in 2033, increasing from US$ 1600 million in 2022, with the CAGR of 10.0% during the period of 2023 to 2033. Demand from Pharmaceutical and Biotechnology Companies and Research Institutes are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Peptide and Oligonucleotide CDMO industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Peptide and Oligonucleotide CDMO key companies include Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Catalent, Inc., Genscript Biotech Corporation, Polypeptide Group, Bachem Holding AG, Wuxi Apptec Co., Ltd. and Ajinomoto Co., Inc., etc. Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA are top 3 players and held % share in total in 2022.
Peptide and Oligonucleotide CDMO can be divided into Peptide CDMO and Oligonucleotide CDMO, etc. Peptide CDMO is the mainstream product in the market, accounting for % share globally in 2022.
Peptide and Oligonucleotide CDMO is widely used in various fields, such as Pharmaceutical and Biotechnology Companies, Research Institutes and Others,, etc. Pharmaceutical and Biotechnology Companies provides greatest supports to the Peptide and Oligonucleotide CDMO industry development. In 2022, global % share of Peptide and Oligonucleotide CDMO went into Pharmaceutical and Biotechnology Companies filed.